Merck & Co Inc (FRA:6MK)
€ 92.9 -0.2 (-0.21%) Market Cap: 236.96 Bil Enterprise Value: 261.27 Bil PE Ratio: 21.36 PB Ratio: 5.93 GF Score: 78/100

Merck & Co Inc at UBS Global Healthcare Conference (Virtual) Transcript

May 18, 2020 / 03:40PM GMT
Release Date Price: €69.6 (-0.54%)
Navin Cyriac Jacob
UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic

Hello. Welcome to the UBS Global Healthcare Conference. This is day 1. Our next presentation or fireside chat is with Merck & Co. I'm very happy to have with me today, EVP and Chief Marketing Officer, Mike Nally; as well as Head of Investor Relations, Peter Dannenbaum. Mike, Peter, thank you so much for joining us today.

Michael T. Nally
Merck & Co., Inc. - CMO & Executive VP

Thanks, Navin. We appreciate the opportunity.

Peter Dannenbaum
Merck & Co., Inc. - VP of IR

Thanks, Navin.

Questions & Answers

Navin Cyriac Jacob
UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic

Great. So we -- we're just going to jump into questions here. We can't escape COVID, obviously, and so maybe I'll just start off with a couple of high-level questions

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot